{"id":"W2971309637","doi":"10.1016/j.jtho.2019.08.009","title":"Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Genentech; National Institutes of Health; Sierra Oncology; Bayer Fund; Lung Cancer Research Foundation; Spectrum Pharmaceuticals; Exelixis; GlaxoSmithKline; Bayer; AstraZeneca; Rexanna's Foundation; Boehringer Ingelheim","keywords":"Medicine; Gemcitabine; Immune checkpoint; Immunotherapy; Immune system; Pharmacology; Immunogenic cell death; Blockade; Combination therapy; Chemotherapy; Oncology; Cancer research; Immunology; Internal medicine; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001137268,0.0001945324,0.0006520731,0.00007239969,0.0001078248,0.000008525039,0.0003381396,0.0002031238,0.00003826872],"category_scores_gemma":[0.00007044194,0.0000885125,0.0001653341,0.000136147,0.000484026,0.00006723963,0.0001236532,0.0003937941,0.000004182508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002704675,"about_ca_system_score_gemma":0.00008306692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008158611,"about_ca_topic_score_gemma":0.00002003791,"domain_scores_codex":[0.9976402,0.001087084,0.0007679317,0.0001534815,0.00008970581,0.0002616066],"domain_scores_gemma":[0.9977646,0.0007181162,0.00115216,0.0002999775,0.00005279778,0.00001236786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0013198,0.0004585154,0.02075548,0.00006008262,0.0002501441,0.000002851629,0.001171197,0.00006864733,0.9016599,0.000006170284,0.00005051427,0.07419672],"study_design_scores_gemma":[0.003373339,0.005549653,0.04402732,0.000173747,0.0001925641,0.0001737347,0.0003448058,0.0000284776,0.943373,0.00003923309,0.002642341,0.00008176464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765009,0.02003533,0.000003548647,0.001459137,0.001089045,0.0008434535,0.000005103736,0.00000271953,0.00006070812],"genre_scores_gemma":[0.9987899,0.0006999334,0.00004233099,0.00002552577,0.0000289041,0.00002567885,0.000004267109,0.00001345552,0.0003700132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07411496,"threshold_uncertainty_score":0.3609435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006612623437811281,"score_gpt":0.2982258224659358,"score_spread":0.2916131990281245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}